Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. 

CEO
Christophe Weber
CEOChristophe Weber
Employees
47,455
Employees47,455
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,455
Employees47,455

TAK Key Statistics

Market cap
47.92B
Market cap47.92B
Price-Earnings ratio
49.61
Price-Earnings ratio49.61
Dividend yield
3.60%
Dividend yield3.60%
Average volume
3.45M
Average volume3.45M
High today
$15.20
High today$15.20
Low today
$15.03
Low today$15.03
Open price
$15.18
Open price$15.18
Volume
2.82M
Volume2.82M
52 Week high
$15.69
52 Week high$15.69
52 Week low
$12.80
52 Week low$12.80

TAK News

Seeking Alpha 2d
Takeda names Lilly's Rhonda Pacheco as President of the U.S. unit

Takeda (NYSE:TAK) said on Thursday that Rhonda Pacheco, who was the group vice president of U.S. cardiometabolic health at Eli Lilly (NYSE:LLY), will join the c...

Takeda names Lilly's Rhonda Pacheco as President of the U.S. unit
TipRanks 4d
Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The associated price target remains the same...

TipRanks 5d
Takeda Pharmaceutical’s Promising Narcolepsy Treatment Drives Buy Rating

Analyst Michael Nedelcovych of TD Cowen maintained a Buy rating on Takeda Pharmaceutical Company, with a price target of $18.00. Elevate Your Investing Strategy...

Analyst ratings

53%

of 15 ratings
Buy
53.3%
Hold
46.7%
Sell
0%

More TAK News

TipRanks 5d
Jefferies says stage set for Centessa to differentiate in narcolepsy

Jefferies notes that Centessa (CNTA) shares rose 18% in reaction to competitors Takeda (TAK) and Alkermes’ (ALKS) narcolepsy data reported at World Sleep as dat...

TipRanks 5d
Takeda reports FirstLight, RadiantLight studies met all endpoints

Takeda (TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton, a potential investigational oral orexin receptor...

TipRanks 5d
Takeda’s Oveporexton Shows Promise in Phase 3 Narcolepsy Trials

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 6d
Takeda announces U.S. FDA approved the sBLA for VONVENDI

Takeda (TAK) announced that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application, sBLA, for VONVENDI, expandi...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.